Illinois pharma company to pay almost $8M after selling OTC drugs under obsolete prescription-only labels
Illinois-based pharma company Akorn, which filed for bankruptcy back in 2020, has now agreed to pay $7.9 million to resolve allegations that it caused Medicare to pay false claims related to generic drugs that had already transitioned to OTC products.
As part of the settlement, the DOJ said Akorn admitted to delaying its conversion of certain generics — the NSAID pain drug diclofenac, and the antihistamines olopatadine and azelastine — from prescription-only to OTC status.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.